TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05586165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder to boost protection against COVID-19
Description: Patients will receive a text message reminding them to enhance their protection against COVID-19 by getting the bivalent booster. The message will contain one link to schedule an appointment at UCLA Health and one link for scheduling an appointment at CVS Pharmacy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder to boost protection against COVID-19
Description: Patients will receive a text message reminding them to enhance their protection against COVID-19 by getting the bivalent booster. The message will contain one link to schedule an appointment at UCLA Health and one link for scheduling an appointment at CVS Pharmacy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder to boost protection against COVID-19
Description: Patients will receive a text message reminding them to enhance their protection against COVID-19 by getting the bivalent booster. The message will contain one link to schedule an appointment at UCLA Health and one link for scheduling an appointment at CVS Pharmacy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flu Tag Along
Description: This message will also encourage patients to protect themselves against the flu by asking for their flu vaccine at the booster appointment (at UCLA Health) or adding the flu vaccine to the COVID-19 vaccine booster appointment (at CVS).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Booster & Flu Bundle
Description: This message will simultaneously encourage patients to enhance their protection against COVID-19 and the flu and will inform them that, to save time, they can bundle two vaccines at once. Patients will learn that at UCLA Health, they can book an appointment for the booster and then ask for the flu vaccine at their appointment; at CVS Pharmacy, they can book one appointment to get both the bivalent COVID-19 booster and the flu vaccine.
Study: NCT06698276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alveolar Ridge Reconstruction
Description: It will be used a combination of two biomaterials for alveolar ridge preservation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alveolar Ridge Reconstruction
Description: It will be used a combination of two biomaterials for alveolar ridge preservation
Study: NCT06301074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10509
Description: In SAD, participants will be assigned to receive either HS-10509 or a matching placebo for a single administration. There are 5 predefined dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), initially starting at 10 mg for cohort 1.~In MAD, participants will assigned to receive HS-10509 or a matching placebo once daily for 28 days. There will be 3 dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), and the dose for each cohort is to be determined.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In SAD, participants will be assigned to receive either HS-10509 or a matching placebo for a single administration. There are 5 predefined dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), initially starting at 10 mg for cohort 1.~In MAD, participants will assigned to receive HS-10509 or a matching placebo once daily for 28 days. There will be 3 dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), and the dose for each cohort is to be determined.
Study: NCT06700395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2029 injection
Description: TQB2029 for injection is a bispecific antibody targeting G Protein-Coupled Receptor, Class C, Group 5, Member D (GPRC5D) and Cluster of Differentiation 3 (CD3) . By recruiting and activating CD3 positive T cells, it induces T cells to kill malignant plasma cells expressing GPRC5D, thereby inhibiting the occurrence and development of tumors.
Study: NCT06720896

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APT-001 topical ophthalmic ointment (spinosad)
Description: APT-001 topical ophthalmic ointment, administered once daily
Study: NCT06301074

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In SAD, participants will be assigned to receive either HS-10509 or a matching placebo for a single administration. There are 5 predefined dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), initially starting at 10 mg for cohort 1.~In MAD, participants will assigned to receive HS-10509 or a matching placebo once daily for 28 days. There will be 3 dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), and the dose for each cohort is to be determined.
Study: NCT04527510

Intervention type: DIAGNOSTIC_TEST
Intervention: Conventional-reading
Description: Two radiologists interpret at least three views of each breast without AI independently.

Intervention type: DIAGNOSTIC_TEST
Intervention: Second-reading
Description: One radiologist reads AB US images without AI first, then combines the indications of AI marks to make the final decision.

Intervention type: DIAGNOSTIC_TEST
Intervention: Concurrent-reading
Description: One radiologist identifies CAD marks first, then quickly browses the entire AB US examination to make the final decision.

Intervention type: DIAGNOSTIC_TEST
Intervention: Tow views-reading
Description: Two radiologists interpret only two views of each breast without AI independently.

Intervention type: DIAGNOSTIC_TEST
Intervention: Handheld US-screening
Description: One radiologist screens the breast cancer using Handheld US and interprets images immediately.
Study: NCT06720896

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle control for APT-001 topical ophthalmic ointment
Description: Vehicle control for APT-001 topical ophthalmic ointment, administered once daily
Study: NCT06721819

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene, Brain Game, and IV Acetaminophen Intervention
Description: Preoperative Sleep Hygiene and Brain game followed by post operative IV acetaminophen administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Three doses of IV acetaminophen (as following ERAS protocol) at 1000mg per dose within 48 hours post operatively.
Study: NCT06720116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sustained natural apophysial glide
Description: The patients will be in the sitting position and asked to move their head in the direction that particularly produces their symptoms. As the participant moves their head, the physiotherapist gently glides the painful vertebra anteriorly and sustains the glide through the movement.~During the application of the glide, the participant should stay symptom free and is instructed to stop moving if any PAIN is produced. This movement was repeated for 10 times for 3 sets, The interval between the sets was 15 to 20 seconds.After mobilization subject had to perform same exercises as conventional group plus conventional physical therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: instrument assisted soft tissue mobilization
Description: The subject will be in comfortable sitting position leaning on a treatment table with the arm crossed to rest the head. After cleaning the skin of the subject and the blade with alcohol swabs, a lubricant (Vaseline) was applied, and a sweeping technique was used to apply a deep yet comfortable soft tissue mobilization on the upper trapezius from origin to insertion for approximately 3 min.~First, M2T blade will be utilized to locate the precise locations of limitation in the affected muscles. Second, the M2T blade was put at 45 degree angle by using convex surface to apply gentle strokes along the muscle. Subjects were instructed that slight hyperemia on the skin is a normal feeling and should subside before the next session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy
Description: the patients will receive conventional physical therapy in the form of Infrared, TENS , stretching exercices, isometric exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy
Description: the patients will receive conventional physical therapy in the form of Infrared, TENS , stretching exercices, isometric exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy
Description: the patients will receive conventional physical therapy in the form of Infrared, TENS , stretching exercices, isometric exercises
Study: NCT06721377

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Novaloc attachment
Description: upper complete dentures and lower complete overdentures. The upper complete denture will be mucosa supported and the lower complete denture will be supported and retained for all patients by two dental implants in the inter-foraminal region \& will be loaded by Novaloc attachment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Equator attachment
Description: upper complete dentures and lower complete overdentures. The upper complete denture will be mucosa supported and the lower complete denture will be supported and retained for all patients by two dental implants in the inter-foraminal region\& will be loaded by Equator attachment.
Study: NCT06721689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEEL-224
Description: PEEL-224 (PEG-\[SN22\]4) is a novel topoisomerase I inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEEL-224
Description: PEEL-224 (PEG-\[SN22\]4) is a novel topoisomerase I inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine is an inhibitor of microtubular formation which is approved by the Food and Drug Administration (FDA) and is commercially available.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: Temozolomide is an alkylating agent which is approved by the FDA and is commercially available.
Study: NCT06721429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dual task exercise group
Description: Dual task exercise group Patients in the dual-task training group will undergo 60-minute conventional physiotherapy sessions three times a week for 8 weeks. Each physiotherapy session will consist of aerobic exercise, strengthening exercises, and balance training. In addition, cognitive exercise training will be incorporated into each session, performed concurrently with the conventional physiotherapy. The cognitive exercises provided in this study are structured to target areas such as memory, verbal fluency, executive functions, calculation, and attentioN Single task exercise group Patients in the single-task training group will undergo 60-minute conventional physiotherapy sessions three times a week for 8 weeks. Each physiotherapy session will consist of aerobic exercise, strengthening exercises, and balance training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: single task group
Description: Single task exercise group Patients in the single-task training group will undergo 60-minute conventional physiotherapy sessions three times a week for 8 weeks. Each physiotherapy session will consist of aerobic exercise, strengthening exercises, and balance training.
Study: NCT06721936

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Multimodal pelviperineal physioterapy group
Description: The multimodal PPT protocol includes:~Pelvic Floor Muscle Training (PFMT): This component includes techniques to raise awareness of the pelvic floor, incorporating both manual and instrumental intravaginal techniques.~Non-Ablative Radiofrequency Therapy (Model: RNG, INDIBA): Applied during all eight sessions, with each session lasting 25 minutes.~Therapeutic Pelvic Health Education: Designed to empower participants with knowledge about their condition and the pelvic-perineal area. This educational intervention aims to enhance understanding, promote self-care, and encourage behaviours that alleviate symptoms associated with GSM

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser CO2 Therapy group
Description: The fractional laser application will be delivery with the following probes:~90° Probe for Incontinence: Maximum power of 40W; 360° Probe for Vaginal Atrophy: Maximum power of 40W and Right-Angle Probe for Vulvar Atrophy: Maximum power of 24W.
Study: NCT06719570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8591A
Description: Fixed dose combination tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8591A
Description: Fixed dose combination tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8591A
Description: Fixed dose combination tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8591A
Description: Fixed dose combination tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8591A
Description: Fixed dose combination tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8591A
Description: Fixed dose combination tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islatravir
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islatravir
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islatravir
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islatravir
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islatravir
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islatravir
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravine
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravine
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravine
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravine
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravine
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravine
Description: Oral tablet
Study: NCT06721065

Intervention type: OTHER
Intervention: Remote Simultaneous Medical Interpreting/RSMI
Description: Remote Simultaneous Medical Interpreting (RSMI), UN-style simultaneous interpreting applied to the medical encounter, which holds tremendous promise for closely approximating a same language encounter, decreasing interpreting errors, and improving outcomes.

Intervention type: OTHER
Intervention: Remote Simultaneous Medical Interpreting/RSMI
Description: Remote Simultaneous Medical Interpreting (RSMI), UN-style simultaneous interpreting applied to the medical encounter, which holds tremendous promise for closely approximating a same language encounter, decreasing interpreting errors, and improving outcomes.

Intervention type: OTHER
Intervention: Remote Consecutive Medical Interpreting/RCMI
Description: Remote Consecutive Medical Interpreting (RCMI; audio consecutive), is the most commonly utilized remote interpreting

Intervention type: OTHER
Intervention: Remote Consecutive Video Medical Interpreting/RCVI
Description: Remote Simultaneous Medical Interpreting (RSMI), UN-style simultaneous interpreting applied to the medical encounter
Study: NCT05219708

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calorie protein supplement
Description: Participants assigned to the intervention group will receive the calorie and protein supplement (i.e. Ensure Original) to be consumed twice daily between meals for 30 days in addition to standard of care for heart failure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard of care for heart failure
Study: NCT06192537

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A role-playing exercise by utilizing an obesity suit in a simulation scenario
Description: All participants will be asked to wear an obesity simulation suit (Unisex obesity Simulation suit, Erler-Zimmer, Germany) and to participate in a standardized scenario that simulates meetings between a person with obesity and a 'registered dietitian'. The 'registered dietitian' will be presented by a professional role-player and the scenario will encompass different levels of weight bias through dialogue and the use of inappropriate equipment.
Study: NCT05232760

Intervention type: DEVICE
Intervention: Supera™ Peripheral Stent System
Description: The device will be employed for treatment of juxta-anastomotic stenosis in failing AV fistula after previous percutaneous angioplasty procedures
Study: NCT06496750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: Participants will receive IV ketamine (0.50mg/kg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump over 45 minutes. Duration of each infusion may be extended by the Study Clinician supervising study medication infusion if slower infusion rate is better tolerated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam Hydrochloride
Description: Participants will receive IV midazolam (0.02mg/kg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump over 45 minutes. Duration of each infusion may be extended by the Study Clinician supervising study medication infusion if slower infusion rate is better tolerated.
Study: NCT04993313

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Undergo verbal counseling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Undergo verbal counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: View photo guide

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Complete questionnaires

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Complete questionnaires
Study: NCT05560061

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait practice on an uneven terrain surface
Description: Participants will walk back and forth on an uneven terrain surface wearing an overhead harness (with zero bodyweight support), at their self-selected comfortable speed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gait practice on a flat terrain surface
Description: Participants will walk back and forth on a level surface wearing an overhead harness (with zero bodyweight support), at their self-selected comfortable speed.
Study: NCT06413472

Intervention type: PROCEDURE
Intervention: Mechanical ventilator adjustment for PCV
Description: In pressure control ventilation (PCV) mode, patients will be ventilated for 5 minutes at a Tslope of 5% and another 5 minutes at 15% for both 1:1 and 1:2 I:E ratios. After each adjustment, screenshots of the mechanical ventilator (P-V loop screenshots) will be obtained . A total of 20 P-V loop screenshots will be captured over a 20-minute period (10 for the 1:2 ratio and 10 for the 1:1 ratio), which will be stored in the ventilators memory. The stored data will then be transferred from the ventilators memory to a computer via a flash drive.

Intervention type: PROCEDURE
Intervention: Mechanical ventilator adjustment for VCV
Description: In volume control ventilation (VCV) mode, patients will be ventilated for 5 minutes at a Tslope of 5% and another 5 minutes at 15% for both 1:1 and 1:2 I:E ratios. After each adjustment, screenshots of the mechanical ventilator (P-V loop screenshots) will be obtained . A total of 20 P-V loop screenshots will be captured over a 20-minute period (10 for the 1:2 ratio and 10 for the 1:1 ratio), which will be stored in the ventilators memory. The stored data will then be transferred from the ventilators memory to a computer via a flash drive.
Study: NCT04278690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HELPix
Description: HELPix parents will receive usual care as above, after which trained staff will generate HELPix patient-/regimen-specific medication instruction sheets and review them with the parent. Instruction sheets include optimized instructions (mL-only, doses appropriately rounded, visuals of recommended tool (e.g. 1-mL syringe best for doses of \<1 mL), explicit frequency information (e.g. 'morning and night' instead of '2x/day') reinforced by pictograms (e.g. sun/moon icons)). For each medication, staff will: 1) review the dose (refer to the pictographic dose diagram, which illustrates optimal dosing tool filled to correct amount), 2) demonstrate the dose using optimal dosing tool, 3) ask parent to 'teachback'/'showback' dose (e.g. parent shows provider how much they would give by pulling back plunger on syringe to right level), 4) provide optimal dosing tool for the parent to take home. We anticipate this process will take \~5-10 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HELPix+Tech
Description: After parent receives usual care and HELPix , trained staff will walk parent through the app on-boarding process to overcome initial barriers to use. Steps: 1) Parent texted link to personalized on-line instructions. 2) Parent clicks link to app. For each medicine: A. Dosing module with optimized instructions (c/w HELPix); parent teachback/showback of dose B. Frequency module supports simplified, explicit intervals (e.g. 'morning and night'), parent chooses convenient times (text reminders sent based on preferences). Time for TECH depends on # medicines and parent baseline knowledge; structured protocol used to see # teachback rounds needed .
Study: NCT05625438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HandyMotion Treatment Program
Description: A pair of sensor-based wireless remote controllers to allow the performance of functional exercises and games that target arm movement.
Study: NCT06450288

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GO
Description: Green Oasis wellness program: include physical exercises, gardening, interaction with the developed website. Participants' general health status and website evaluation will be measured at T0 (baseline), T1 (3 months), T2 (9 months), using standardized questionnaires.~Study Design: pre-post study, 50 participants will be recruited from the Concordia Tsat Sing Kong transitional housing estate.
Study: NCT05121012

Intervention type: OTHER
Intervention: Study procedures
Description: All participants will undergo a collection of demographic data, a neurological examination and administration of clinical scales relevant for MSA-P. All participants will undergo a collection of venous blood sample for routine analyses.~Participants will undergo one PET scan with the tracer \[11C\]UCB-J, and one PET scan with the tracer \[18F\]FDG. All participants will also undergo one MRI scan.~Participants will also undergo one lumbar puncture (optional).~All procedures will be performed at baseline and after one-year follow-up.
Study: NCT05418452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: metformin (MF), an antidiabetic agent, has been successfully used as a local drug delivery agent in periodontitis patients. Literature has suggested that MF possesses the osteogenic potential and induces the growth of osteoblast precursor cells. Therefore, several human studies have reported the use of MF alone or combined with PRF in the treatment of bony defects